fas nf-kappa b signalling modulate dependence lung cancers mutant egfr 
human lung adenocarcinomas activating mutations egfr epidermal growth factor receptor often respond treatment egfr tyrosine kinase inhibitors tkis magnitude tumour regression variable transient12 heterogeneity treatment response result genetic modifiers regulate degree tumour cells dependent mutant egfr pooled rna interference screen show knockdown fas several components nf-kappa b pathway specifically enhanced cell death induced egfr tki erlotinib egfr-mutant lung cancer cells activation nf-kappa b overexpression c-flip ikk also known cflar ikbkb respectively silencing kappa b also known nfkbia rescued egfr-mutant lung cancer cells egfr tki treatment genetic pharmacologic inhibition nf-kappa b enhanced erlotinib-induced apoptosis erlotinib-sensitive erlotinib-resistant egfr-mutant lung cancer models increased expression nf-kappa b inhibitor kappa b predicted improved response survival egfr-mutant lung cancer patients treated egfr tki data identify nf-kappa b potential companion drug target together egfr egfr-mutant lung cancers provide insight mechanisms tumour cells escape oncogene dependence 
